Caplyta for Depression and Migraine
No, Caplyta (lumateperone) should not be used for migraine prevention—it has no FDA approval or evidence for this indication—but it is FDA-approved and effective as adjunctive therapy for treatment-resistant major depressive disorder. 1
FDA-Approved Indications
Caplyta is FDA-approved for three specific conditions 1:
- Schizophrenia in adults
- Bipolar I or II depression (monotherapy or adjunctive with lithium/valproate)
- Major depressive disorder as adjunctive therapy with antidepressants
The drug has no approval or indication for migraine prevention or treatment. The 2025 ACP migraine prevention guideline 2 does not mention lumateperone among any of the pharmacologic options for episodic migraine, which include beta-blockers, anticonvulsants, CGRP antagonists, and other established agents.
Efficacy for Treatment-Resistant Depression
For deep/treatment-resistant depression, Caplyta 42 mg as adjunctive therapy demonstrates robust efficacy with clinically meaningful improvements:
Evidence Quality
The highest quality recent evidence comes from two Phase 3 randomized controlled trials (2024-2025) 3, 4:
- Study 501: Lumateperone + antidepressant showed superior improvement versus placebo + antidepressant on MADRS total score (difference: -4.9 points; effect size: -0.61; P<0.0001) 3
- Study 502: Similar results with MADRS improvement (difference: -4.5 points; effect size: -0.56) 4
Both studies enrolled adults with MDD who had inadequate response to 1-2 antidepressants in the current episode (MADRS ≥24 at baseline).
Broad Symptom Improvement
Lumateperone improved multiple depression domains 5:
- Anhedonia symptoms (effect size: -0.50)
- 9 out of 10 individual MADRS items
- Patient-reported depression (QIDS-SR-16)
- Clinical Global Impression severity scores
Network Meta-Analysis Ranking
A 2026 network meta-analysis comparing all FDA-approved atypical antipsychotics for adjunctive MDD treatment ranked lumateperone as having the highest likelihood of being most efficacious across endpoints 6.
Safety Profile for Depression
Caplyta has a favorable safety profile compared to other atypical antipsychotics, particularly regarding metabolic effects:
Key Safety Advantages 7, 6:
- No weight gain: Only 0.4% had ≥7% weight increase (vs 1.3% placebo)
- Minimal cardiometabolic changes
- Low prolactin elevation
- Minimal extrapyramidal symptoms (EPS rate: 5.8% vs 1.7% placebo)
Common Side Effects 7, 3, 4:
Most treatment-emergent adverse events were mild-to-moderate:
- Dry mouth (10.8%)
- Fatigue (9.5%)
- Dizziness
- Somnolence
- Nausea
- Tremor (5.0%, mean duration 11.9 days)
Important Caveat
Discontinuation due to adverse events was higher with lumateperone (8.7-12.4%) versus placebo (0.8%) 7, 3, 4. This is clinically significant and patients should be counseled about tolerability during the first weeks of treatment.
Clinical Algorithm for Use
For treatment-resistant MDD:
- Confirm inadequate response to at least one adequate antidepressant trial (per 2023 ACP depression guideline 8)
- Add Caplyta 42 mg once daily in the evening while continuing current antidepressant
- Monitor for early adverse events (first 2-4 weeks) given higher discontinuation rates
- Assess response at 6 weeks using validated depression scales
- Watch specifically for dizziness, somnolence, and dry mouth
For migraine prevention: Do not use Caplyta. Instead, follow the 2025 ACP migraine guideline 2 which recommends evidence-based options including propranolol, topiramate, valproate, CGRP antagonists, or other established preventive agents.
Bottom Line
Caplyta represents an effective adjunctive option for treatment-resistant depression with superior metabolic safety compared to other atypical antipsychotics, but it has absolutely no role in migraine management. The question conflates two unrelated conditions—use Caplyta only for its FDA-approved depression indication.